ArticleBritish journal of clinical pharmacology2026
The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis work aimed to correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed nonsteroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known off-target polypharmacology.
methodsPhysicochemical and polypharmacology data were curated from the Electronic Medicines Compendium, FDA New Drug Applications documents, and ChEMBL database. Suspected ADRs and fatalities were curated from the United Kingdom Medicines and Healthcare products Regulatory Authority (MHRA) Yellow card spontaneous reporting scheme. The number of daily doses (dd) was extrapolated from OpenPrescribing and NHS Digital secondary care medicines data.
resultsA total of n = 2522 suspected ADRs were associated with 42 903 000 dd of NSARAs usage in the United Kingdom. The highest number of ADRs were associated with enzalutamide (n = 1091) and bicalutamide (n = 738). Enzalutamide was found to have the most off-target pharmacological interactions of the NSARAs studied (n = 4) including potent inhibition of γ-aminobutyric acid, GABA receptor (IC
conclusionsSuspected skin and subcutaneous ADRs approached statistical significance and were interrogated for chemical and pharmacological connections for the first time with the aid of matched molecular pair (MMP) analysis. A potential correlation to nervous system disorders and cardiac arrhythmia for the GABA and hERG inhibitors, enzalutamide and apalutamide, respectively was identified. Darolutamide's interaction with the 5-HT (SERT) transporter may influence ADRs associated with cardiac and hepatobiliary SOCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.